MBL establishes a new R&D and manufacturing site for in vitro diagnostic products and services in Shenzhen, China
Shenzhen, China - September 17, 2021 - Medical and Biological Laboratories Co., Ltd. (President & CEO: Kimimasa Yamada, “MBL”), a JSR Life Sciences Company, announced that its subsidiary MBL Shenzhen Biotech Co., Ltd. (“MBLS”) has been established in full-scale operation as a new R&D and manufacturing site for in vitro diagnostic products and services in China.
MBL has been manufacturing and selling raw materials for diagnostic reagents in the rapidly growing Chinese market. Through more flexible and quick services newly added by operation of MBLS, we aim to increase the satisfaction of customers, including not only diagnostic reagent manufacturers but also pharmaceutical manufacturers, in China.
(4) Address Wisdom Homeland Phase2 Block 3A Building 12 Block, Baolong Residential District, Baohe Avenue No. 76, Longgang Shenzhen Guangdong 518000 China
Contact details
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
MBL Co-sponsors a Seminar on MEBRIGHT™ genitalium Plus DR Kit at the 98th JAID / the 72nd JSC Conference
MBL to co-sponsor a seminar on MEBRIGHT™ genitalium Plus DR Kit at the 98th JAID/72nd JSC Conference, focusing on STD treatment advancements. Learn more on June 27th, 2024.
MBL announces exclusive license agreement for Anti-Integrin αvβ6 Antibody with Immune-related Adverse Events colitis
MBL has announced that it has entered into an exclusive license agreement with Kyoto University and Kindai University regarding the detection of Anti-Integrin αvβ6 autoantibodies as an indicator of...
MEBGEN™ BRAF 2 Kit Receives MHLW Approval as a Companion Diagnostic for Use with Patients with Thyroid Cancer
With this approval, the MEBGEN™ BRAF 2 Kit is expected to contribute to the timely personalized treatment for patients with radically unresectable thyroid cancer based on the presence or absence of...
Notice of Approval for First-Class Marketing License for Medical Devices
With the acquisition of the First-Class Marketing License for Medical Devices, MBL will be able to market highly controlled medical devices, including genetic testing systems using NGS.
Launch of a New Chemiluminescence Immunoassay Analyzer “iStar500”
The iStar is a highly automated mono-test analyzer based on CLIA technology. The compact & integrated design, combined with highly sensitive CLIA technology, makes it an ideal choice for emergency ...